The remarkable capacity of immunotherapies to induce durable regression in some patients
with metastatic cancer relies heavily on T cell recognition of tumor-presented antigens. As …

Liposomes and liposome-derived nanovesicles such as archaeosomes and virosomes have
become important carrier systems in vaccine development and the interest for liposome …

Background Effective maintenance therapies after chemoradiotherapy for lung cancer are
lacking. Our aim was to investigate whether the MUC1 antigen-specific cancer …

Peptides cancer vaccines are designed based on the epitope peptides that can elicit
humoral and cellular immune responses targeting tumor‐associated antigens (TAAs) or …

Recent progress in chimeric antigen receptor-modified T-cell (CAR-T cell) technology in
cancer therapy is extremely promising, especially in the treatment of patients with B-cell …

Chemotherapy, radiation, and growth inhibitory drugs preferentially eliminate actively
growing cancer cells. Cancer recurrence is currently thought to be due to nondividing cancer …

Background TG4010 is a recombinant viral vector expressing both the tumor-associated
antigen MUC1 and Interleukine-2. This vector is based on the modified virus of Ankara, a …

Molecular targeted therapy has revolutionized the landscape of cancer treatment due to
better therapeutic responses and less systemic toxicity. However, therapeutic resistance is a …

Background Non‐small cell lung cancer (NSCLC) is the most common lung cancer,
accounting for approximately 80% to 85% of all cases. For people with localised NSCLC …

MUC1 is overexpressed and aberrantly glycosylated in more than 60% of pancreatic ductal
adenocarcinomas. The functional role of MUC1 in pancreatic cancer has yet to be fully …